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Abstract 
Reports of resurgence in invasive group A streptococcal (GAS) infections come mainly from affluent 
populations with infrequent exposure to GAS. In the tropical Northern Territory (NT) of Australia, high 
incidence of invasive GAS disease is secondary to endemic skin infection; serotype M1 clones are rare in 
invasive infection; the diversity and level of exposure to GAS strains is high and no particular strains 
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associated with skin infection in isolates elsewhere (Bessen, D., C.M. Sotir, T.M. Readdy, and S.K. 
Hollingshead.1996. J. Infect. Dis. 173:896-900) and subversion of the host plasminogen system by GAS is 
thought to contribute to invasion in animal models. Here, we describe the relationship between 
plasminogen-binding capacity of GAS isolates, PAM genotype and invasive capacity in 29 GAS isolates 
belonging to 25 distinct strains from the NT. In the presence of fibrinogen and streptokinase, invasive 
isolates bound more plasminogen than isolates from uncomplicated infections (p ≤ 0.004). Only PAM-
positive isolates bound substantial levels of plasminogen by a fibrinogen-streptokinase-independent 
pathway (direct binding). Despite considerable amino acid sequence variation within the A1 repeat region 
of PAM where the plasminogen-binding domain maps, the critical lysine residue was conserved. 
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Abstract  
Reports of resurgence in invasive group A streptococcal (GAS) infections come mainly 
from affluent populations with infrequent exposure to GAS. In the tropical Northern 
Territory (NT) of Australia, high incidence of invasive GAS disease is secondary to 
endemic skin infection; serotype M1 clones are rare in invasive infection; the diversity 
and level of exposure to GAS strains is high and no particular strains dominate. 
Expression of a plasminogen-binding group A streptococcal M-like protein (PAM) has 
been associated with skin infection in isolates elsewhere (Bessen, D., C.M. Sotir, T.M. 
Readdy, and S.K. Hollingshead.1996. J. Infect. Dis. 173:896-900) and subversion of the 
host plasminogen system by GAS is thought to contribute to invasion in animal models. 
Here, we describe the relationship between plasminogen-binding capacity of GAS 
isolates, PAM genotype and invasive capacity in 29 GAS isolates belonging to 25 distinct 
strains from the NT. In the presence of fibrinogen and streptokinase, invasive isolates 
bound more plasminogen than isolates from uncomplicated infections (p ≤ 0.004). Only 
PAM-positive isolates bound substantial levels of plasminogen by a fibrinogen-
streptokinase-independent pathway (direct binding). Despite considerable amino acid 
sequence variation within the A1 repeat region of PAM where the plasminogen-binding 
domain maps, the critical lysine residue was conserved.  
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Introduction 
  GAS cause a variety of superficial infections such as impetigo, as well as invasive 
diseases including bacteremia, necrotizing fasciitis and myositis. A recent survey from 
the tropical “Top End” of the NT found a high incidence of invasive GAS disease, with 
rates of bacteremia in non-Aboriginal people (9) comparable to those constituting the 
resurgence in GAS bacteremia described elsewhere in the Western World (30, 40). 
Amongst Aboriginal people of the Top End the incidence of GAS bacteremia is 5 times 
that of non-Aboriginal people living in the same region (9).  
  In addition to the high incidence of severe GAS infection in the NT, several other 
epidemiological features characterise the GAS isolates from this vast geographic region. 
Up to 60% of isolates from the NT do not react with available M-typing sera (29), while 
some react with more than one, giving an ambiguous M-typing result (28). This has lead 
to the development of the vir typing system, consisting of restriction fragment length 
polymorphism analysis of the mga regulon (15). Vir-typing of strains causing GAS 
infection in Aboriginal communities has demonstrated that the diversity and turnover rate 
of these strains is much higher than those reported elsewhere (8). There has been no 
evidence of a resurgence in severe invasive infections due to particular strains or any 
invasive infection associated with M1 clones (9) which have been responsible for much 
of the recent resurgence in GAS bacteremia reported elsewhere (32). A recent NT study 
examining 100 GAS isolates found only 2 M1 isolates, which were not clonally related or 
isolated from invasive disease cases (R. J. Towers, G. Mollinari, K. Bruder-Okando, D. 
Zell, A. Delvecchio, P. Fagan, S. Gardam, M. Hibble, B. Currie, M. J. Walker, K. S. 
Sriprakash, and G. S. Chhatwal, Abstr. XV Lancefield International Symposium on 
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Streptococci and Streptococcal Diseases, abstr. P1.02, 2002) Similarly, a study of 
invasive GAS disease from 1996-2001 in Townsville Hospital, North Queensland, found 
only 5.5% were emm1 (gene for M1 protein) sequence type (R. Norton, H. V. Smith, N. 
Wood, E. Siegbrecht, A. Ross, and N. Ketheesan, Abstr. XV Lancefield International 
Symposium on Streptococci and Streptococcal Diseases, abstr. O2.2, 2002)  
  The most common focus of invasive infection in the NT is the skin, with no 
episodes of pharyngitis underlying GAS bacteremia in a 6-year retrospective review (9). 
Rates of GAS skin infection are extremely high, due in part to infection of scabies 
lesions, with impetigo prevalence rates of up to 70% reported (17). 
  An important role for plasminogen in invasion of host tissue barriers has been 
recognised in several bacterial species (6, 12, 24). Plasminogen is the zymogen of the 
broad-spectrum serine protease plasmin, which degrades fibrin clots and extracellular 
matrix (ECM) components such as fibronectin, laminin, vitronectin, and proteoglycans. It 
also activates matrix prometalloproteases -1, -3, -9 and -14, which cleave other 
components of the ECM such as collagen (41). Plasminogen is activated to plasmin by 
the host activators tissue plasminogen activator (tPA) and urokinase plasminogen 
activator (uPA). Co-localisation of plasminogen and tPA to fibrin(ogen) results in 
fibrinolysis, while uPA is the major cell-bound activator, functioning in cellular invasion 
(23). Bacterial plasminogen activators include Pla of Yersinia pestis and streptokinase of 
group A, C and G streptococci (6).  
  Plasminogen binds to the high affinity GAS plasminogen receptors plasminogen-
binding group A streptococcal M-like protein (PAM) (3) and streptococcal enolase (SEN) 
(26) by its amino-terminal lysine-binding kringle domains (22). Cell-surface 
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glyceraldehyde-3-phosphate dehydrogenase, designated Plr (42) or streptococcal 
dehydrogenase (SDH) (27), has been reported to bind plasminogen with low affinity. 
  Plasminogen binds to PAM via lysine residues present in two tandem repeats, A1 
and A2, in the amino-terminal variable region of PAM (3). The lysine residue found in 
A1 is responsible for the majority of the plasminogen binding capacity of PAM (44). This 
interaction is at least partly mediated by kringle 2 of plasminogen (43).  
The PAM phenotype and genotype have been found to be selectively distributed 
among GAS strains of emm pattern D (33), reported to be a genetic marker for skin as the 
preferred tissue site for infection (4), (5). It has been suggested that plasminogen binding 
capacity of PAM may be important for persistence of GAS in skin infection. Proteolytic 
capacity of PAM-bound plasminogen on the surface of GAS may allow the breakdown of 
fibrin barriers formed during wound healing. Alternatively, sequestering of plasminogen 
by GAS may diminish the plasminogen available for host immune response at the 
infection site (42).   
An indirect plasminogen-binding pathway in GAS with a requirement for 
streptokinase and fibrinogen has also been described (38, 39). Plasminogen binding by 
this pathway has been correlated with the fibrinogen-binding capacity of various GAS 
strains (39), and it has been suggested that fibrinogen bound to M or M-related proteins 
mediates capture of fibrinogen-streptokinase-plasminogen complexes to the GAS cell 
surface (11, 38). Evidence for the formation of the trimolecular complex using purified 
protein components has been reported previously (34).  The trimolecular complex bound 
to the GAS cell surface possess both plasmin (38) and plasminogen-activator (13) 
activities.  
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  In a mouse skin infection model, GAS preincubated with human plasminogen, 
human fibrinogen and exogenous streptokinase were more invasive than untreated 
bacteria (25).  However, a study of clinical isolates found no significant association 
between plasminogen binding and the invasive potential of the isolates, although the 
mean plasmin activity of blood isolates was higher than that of throat isolates (37). To 
date, there has been no definitive epidemiological evidence supporting a relationship 
between the human plasminogen system and GAS in accentuating virulence (6).  
  Reports suggesting an important role for plasminogen in both GAS skin disease 
and invasive disease led us to investigate aspects of plasminogen binding by GAS isolates 
from the NT where a high incidence of both clinical manifestations of GAS infection 
prevails. Isolates from uncomplicated infections and invasive disease cases were 
examined for plasminogen binding by the direct and fibrinogen-streptokinase-dependent 
(FSD) pathways, fibrinogen binding capacity, PAM genotype, emm-pattern and emm 
sequence type.  
 
Materials and Methods 
  Proteins. Glu-plasminogen was purified from human plasma as previously 
described (1). Human fibrinogen (essentially plasminogen-free; Sigma, St Louis, MO) 
was tested to confirm the absence of contaminating fibronectin by Western blotting with 
a rabbit polyclonal antibody against human fibronectin (Sigma, St Louis, MO). 
Plasminogen and fibrinogen were labelled with 
125
I (Amersham Biosciences, Arlington 
Heights, IL) by the chloramine T method (20). All labelled proteins were analysed for 
homogeneity by gel electrophoresis and autoradiography in comparison with non-labelled 
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proteins.  
  Bacterial strains, media and growth conditions. Group A streptococcal isolates 
were collected from patients in the Northern Territory between 1990 and 1998.  Isolates 
were collected from either invasive infections (from normally sterile tissues such as 
blood) or uncomplicated infections (from non-sterile tissues such as skin). The isolates 
were largely from Aboriginal Australians due to high endemicity of GAS disease in this 
population (9). GAS isolates were cultured overnight at 37ºC in Todd-Hewitt broth 
(THB; Difco, Detroit, MI) supplemented with 1% yeast extract. Cells were washed twice 
with 5ml of PBS (0.01M phosphate, 0.14M sodium chloride, pH 7.4) containing 0.05% 
Tween 20 (PBST) and resuspended to an optical density (OD) of 1.0 at 600nm in PBST 
with 100mM of the lysine analogue epsilon-amino caproic acid (eACA; Sigma, St Louis, 
MO) added where appropriate.  
  Molecular typing and emm pattern. Vir typing (15) was performed as 
previously described. The method used to determine emm sequence types was modified 
from the Streptococcus pyogenes emm sequence database (2) and is described briefly 
here. Chromosomal DNA was prepared using the DNeasy Tissue Extraction kit (Qiagen, 
Hilden, Germany). PCR-amplification of chromosomal DNA was performed using 
primers emm1 and emm2 (2) or using primers VUF and SBR as previously described 
(16). The resulting PCR product was purified using a MinElute Gel Extraction Kit 
(Qiagen, Hilden, Germany) and sequenced with BigDye™ Ready Reaction Mix (Applied 
Biosystems, Boston, MA) using emm 1 or emmseq2 primers. The resulting sequences 
were compared to emm sequences in the Streptococcus pyogenes emm sequence database 
(2). 
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  Determination of emm pattern was performed as previously described (4, 18) 
except that annealing temperatures were varied between 56ºC and 62ºC.   
  Binding assays. The method used to measure the binding of radiolabelled 
proteins was
 
essentially as previously described (10). Labelled protein (approximately 
70ng of 
125
I-plasminogen, or 45ng of 
125
I-fibrinogen) was added to 250µl of the cell 
suspension and incubated for 45 min at room temperature. When required fibrinogen 
(1.5-fold molar excess compared to plasminogen) and streptokinase (10-fold molar 
excess compared to plasminogen; Sigma, St Louis, MO) were added to the cell 
suspension. Equimolar plasminogen and streptokinase were added to the cell suspension 
for selected assays. The cells were sedimented by centrifugation and the supernatant 
carefully aspirated. Pellet-associated radioactivity was measured using an automatic 
gamma counter (Wallac) and the results were expressed as a percentage of input 
radioactivity. All measurements were determined in triplicate.  
  DNA methods. Chromosomal DNA was isolated from streptococcal isolates 
using the Instagene method (Bio-Rad Laboratories, Hercules, CA). Genes encoding M 
and M-like proteins from GAS strains were PCR-amplified from chromosomal DNA 
using primers M1 and M2 (3). The SEN gene was PCR-amplified from chromosomal 
DNA using SENF1 and SENR1 (Table 1). PCR cycling temperatures were 94ºC, 50ºC 
and 72ºC for denaturation, annealing and extension reactions respectively. Thirty and 
thirty-two cycles were used for amplification of genes encoding M and SEN, 
respectively.  
  For Southern hybridisation (31) of PAM genes, PCR products amplified using the 
M1 and M2 primers were resolved by agarose gel electrophoresis, transferred to a 
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Hybond N+ Nylon membrane (Amersham Biosciences, Arlington Heights, IL) and cross-
linked to the membrane using a UV Stratalinker 1800 (Stratagene, La Jolla, CA). 
Prehybridisation, hybridisation and detection were performed using a digoxigenin-11-
ddUTP labelling kit (Boehringer Mannheim, Mannheim, Germany) according to the 
manufacturer’s instructions, except that blocking was performed with 5% skim milk 
powder in maleic acid buffer (0.1M maleic acid, 0.15M NaCl, pH 7.5). The PAM 
oligonucleotide probe (5’-CGACTTAAAA(A/G)CGAGAGACATGA-3’) is homologous 
to the sequence corresponding to the most conserved residues (RLKN/SERH) in the A1 
(DAELQRLKNERHE) and A2 (EAELERLKSERHD) repeats of PAM. The probe was 
3’-end labelled with digoxygenin-11-ddUTP according to the manufacturer’s instructions.  
 PCR products amplified using the M1 and M2 primers from PAM-positive GAS 
strains were cloned into plasmid pCR®2.1 using the TA Cloning Kit (Invitrogen, 
Carlsbad, CA). Escherichia coli INVαF’ (Invitrogen, Carlsbad, CA) were transformed 
with plasmids containing the PAM genes according to the manufacturer’s instructions. 
Plasmid DNA was extracted using a QIAprep Spin Miniprep kit (Qiagen, Hilden, 
Germany). Plasmids were screened for the presence of the cloned PAM gene by Southern 
hybridisation. 
 DNA sequences were determined using Terminator Ready reaction mix (PE 
Applied Biosystems, Boston, MA) and appropriate primers (Table 1).  
Statistical analysis. Pearson’s χ
2 
analysis was used to determine associations 
between genetic markers and invasive classification. 
 
Binding data were analysed for 
differences between PAM status and infection classification using two-way analysis of 
variance (ANOVA). Where data (or arcsine-transformed data) did not fit the assumptions 
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for two-way ANOVA, an unpaired Student’s t test, Welch ANOVA (unequal variances) 
or Wilcoxan/Kruskal-Wallis Rank Sum test (non-parametric) was used to compare 
groups separately. A paired Student’s t test was used to analyse responses of isolates to 
different experimental conditions. Pearson’s (parametric) or Spearman’s (non-parametric) 
correlation coefficients (r) were used to describe the relationships between cell-surface 
binding of radiolabelled proteins.  
Amino acid sequence accession numbers.  The DNA sequences of the A1 and 
A2 repeat regions of PAM genes were deposited in Genbank. The corresponding 
accession numbers for each of the PAM-positive isolates is given in parentheses: NS10 
(AY351846); NS1133 (AY351847); NS59 (AY351848); NS50.1 (AY351849); NS32 
(AY351850); NS13 (AY351851); NS53 (AY351852); NS253 (AY351853); NS223 
(AY351854); NS265 (AY351855); NS88.2 (AY351856); NS455 (AY351857); and 
NS696 (AY351858).  
 
Results 
Genetic analysis of GAS isolates. Characteristics of the 29 clinical isolates from 
invasive cases (n = 14) and uncomplicated (n = 15) GAS infections are given in Table 2. 
The isolates showed considerable genetic diversity, with 25 vir types, 24 emm sequence 
types and 4 of the five major emm patterns represented (Table 2). Together the 29 isolates 
represent 25 genetically distinct strains which are thus not epidemiologically linked. 
There were 3 small clusters of isolates which were found to be genetically 
indistinguishable based on the typing methods used. These were NS730 and NS733 (vir 
type 2.2, emmST 90 and emm pattern E); NS10, NS13 and NS59 (vir type 24, emmST 53 
PLASMINOGEN BINDING BY NORTHERN TERRITORY S. PYOGENES 
 
12
 
and emm pattern D); and NS455 and NS253 (vir type 29.1, emmST 52 and emm pattern 
D). In this study emm pattern was not significantly associated with invasive disease (p ≤ 
0.148). 
GAS isolates were then examined for presence of genes encoding the high affinity 
plasminogen binding receptors, SEN and PAM, and for genetic variation within the 
plasminogen binding domains of these receptors. All the isolates contained the SEN gene 
with both plasminogen binding C-terminal lysine residues (14, 26) conserved (data not 
shown). Of the 14 isolates from invasive disease cases, 5 were PAM-positive by Southern 
hybridisation analysis, while 8 of the 15 isolates from uncomplicated infections were 
PAM-positive.  
The A1 and A2 repeats of the PAM sequences demonstrate divergence compared 
to the repeats in the prototype PAM (3) (Figure 1). Isolates of the same vir type had 
identical A1 and A2 repeats. Except for NS696, all the 13 PAM-positive isolates 
possessed emm pattern D mga regulon.  
  Plasminogen binding by GAS isolates. To investigate whether plasminogen 
binding is associated with the invasive phenotype in NT isolates, isolates from invasive 
disease and uncomplicated infections were compared for this property. Binding by the 
direct and FSD pathways was measured  (Figure 2). In the presence of eACA, a 
competitive inhibitor of lysine-dependent binding, binding was reduced to 4% of input 
plasminogen (range 2-11%), except in isolate NS 88.2, which showed high level of lysine 
independent binding of plasminogen (17%; data not shown).  
Presence of the PAM gene had a significant positive effect on plasminogen 
binding by both the direct (p ≤  0.036) and FSD (p ≤  0.026) pathways. Invasive isolates 
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bound more plasminogen directly than isolates from uncomplicated infections in the 
PAM-positive group (p ≤  0.027). In the PAM-negative group all of the isolates displayed 
minimal reactivity with plasminogen (7% mean) and there was no difference in direct 
plasminogen binding capacity between invasive and non-invasive isolates (p ≤  0.180). 
In the presence of streptokinase and fibrinogen, isolates from invasive disease 
cases bound more plasminogen than isolates from uncomplicated infections (p ≤  0.004 
for effect of invasive phenotype in 2-way ANOVA; p ≤  0.026 for effect of PAM 
genotype). There was an absolute requirement for both fibrinogen and streptokinase to 
significantly increase plasminogen binding in a representative isolate (Figure 3). The 
enhancement of plasminogen binding did not occur when streptokinase alone or 
fibrinogen alone was added (p ≥ 0.05 for both conditions).  
Within the small clusters of genetically indistinguishable isolates identified, 
invasive isolates bound more plasminogen than isolates from uncomplicated infection by 
both the direct and FSD pathways in each case.  
Relationships between fibrinogen and plasminogen binding. The relationship 
between fibrinogen-binding and FSD plasminogen binding by the NT GAS isolates was 
investigated to determine whether the data is consistent with a model of capture of 
fibrinogen-streptokinase-plasminogen complexes by fibrinogen binding proteins (37).  
Binding of fibrinogen to GAS isolates is shown in Figure 4A. PAM-positive isolates 
bound more fibrinogen than PAM-negative isolates (p ≤ 0.019). There was a correlation 
between fibrinogen binding and FSD plasminogen binding among PAM-positive isolates 
(r
 
= 0.775, p ≤ 0.002; Figure 4A). By contrast PAM-negative isolates do not show such 
correlation (r
 
= 0.035, p ≤ 0.897). Nor was there a correlation between fibrinogen binding 
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and the increase in plasminogen binding resulting from addition of streptokinase and 
fibrinogen (r = 0.007, p ≤ 0.778)  
In PAM-positive isolates there was a strong correlation between direct 
plasminogen binding and FSD plasminogen binding (r = 0.902, p ≤ 0.0001; Figure 4B), 
and between direct plasminogen binding and fibrinogen binding (r = 0.806 , p ≤ 0.001).  
 
Discussion 
Subversion of the host plasminogen system renders a pathogen capable of 
degrading ECM proteins and activating a cascade of metalloproteases, conferring the 
potential to invade host tissue barriers. An important role for plasminogen in the invasive 
process of GAS has been demonstrated in an animal model (25), but as yet no definitive 
epidemiological evidence has supported the hypothesis that the human plasminogen 
system plays a role in GAS invasive disease.  
To our knowledge this is the first report to demonstrate a significant relationship 
between acquisition of plasminogen by human clinical isolates from a range of emm 
sequence types of GAS and propensity to cause invasive diseases. Amongst PAM-
positive isolates which are capable of binding plasminogen directly, invasive isolates 
bind more plasminogen both directly, and by a FSD pathway which is correlated with 
direct plasminogen binding. Within the small clusters of PAM-positive isolates 
indistinguishable by the genotyping methods used, invasive isolates always bound more 
plasminogen than isolates from uncomplicated infection by both the direct and FSD 
pathways. Possible reasons for plasminogen binding differences in these clusters might 
include variation in expression levels or differential post-translational processing or 
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degradation. For PAM-negative isolates which do not bind substantial amounts of 
plasminogen directly, invasive isolates bind more plasminogen by the FSD pathway. 
Together these results suggest that plasminogen acquisition may be an important 
virulence determinant of GAS. The diversity of emm sequence types represented in this 
collection of isolates suggests that these relationships between plasminogen binding and 
invasive capacity do not depend on a small number of dominant clones. 
The extent of direct plasminogen binding (4-81%) in this study is similar to that 
found in a previous study (9-69%) (36). Except for the conserved lysine residue in the A1 
region, thought to be responsible for the majority of plasminogen binding (44) the 
plasminogen binding domain in PAM is highly divergent. The fact that PAM-negative 
isolates show only moderate reactivity with plasminogen despite the presence of the gene 
for SEN, another plasminogen binding protein, suggests that SEN may not play a major 
role in plasminogen sequestration.  
Isolates from invasive disease cases bind significantly more plasminogen by the 
FSD pathway than isolates from uncomplicated infections. Plasminogen acquisition by 
the FSD pathway may therefore be a determinant for the invasive propensity. Plasmin 
activity owing to the FSD pathway is resistant to inhibition by plasma proteins, and has a 
half-life of over 4 h as opposed to 20 min for plasmin activity owing to direct 
plasminogen binding (38). The plasminogen-activation function of the complex also 
generates plasmin which can bind to surface receptors despite the presence of host 
physiological inhibitors (13). The significant enhancement of plasminogen binding has an 
absolute requirement for both fibrinogen and streptokinase, a result consistent with earlier 
reports (38, 39). 
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The difference in fibrinogen binding between PAM-positive and PAM-negative 
strains, correlation between fibrinogen and PAM-mediated plasminogen binding, and 
further enhancement of plasminogen binding by a combination of streptokinase and 
fibrinogen in PAM-positive isolates point to the occurrence of another receptor 
concomitant with PAM, or PAM itself may be endowed with dual receptor activity. 
In contrast to PAM-positive isolates, neither the basal levels of plasminogen 
binding, nor the enhancement of the binding by the FSD pathway was correlated with 
fibrinogen binding to the surface of the PAM-negative isolates. This underscores the 
different mechanisms of plasminogen binding between PAM-positive and PAM-negative 
GAS strains. 
 
The plasminogen system is only one of several factors implicated in the invasive process 
of GAS. The streptococcal pyrogenic exotoxin B of GAS possesses cysteine protease 
activity also capable of degrading host ECM (7, 21). The reason for lack of association 
between the plasminogen system and GAS invasive disease in the previous report (37) 
may simply reflect the analysis of the plasminogen system in isolation, and not as one of 
several factors in an overall proteolytic model. In this regard, overall proteolytic activity 
of human isolates has been associated with clinical signs of invasion (19, 35). 
Alternatively, these previous findings may simply be indicative of the complexity of the 
interaction of GAS and plasminogen in the invasive process. As Boyle and Lottenberg 
(1997) note, analysis of this complex system, involving at least four proteins, is 
particularly difficult as the bacterial components may be expressed only under certain 
environmental conditions (6).  
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In summary, we have demonstrated that GAS isolates from NT invasive disease 
cases belonging to a wide range of emm sequence types acquire more plasminogen than 
isolates from uncomplicated infections by a pathway requiring fibrinogen and 
streptokinase as cofactors. Among isolates containing the PAM gene, invasive isolates 
also bind more plasminogen directly. Subversion of the plasminogen system may be an 
important virulence determinant in GAS, and future work will focus on identifying the 
basis for higher plasminogen binding by invasive isolates within and between GAS 
genotypes. 
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Figure Legends  
Figure 1.  Translated DNA sequences of the A1 and A2 repeats of the 13 PAM-
positive isolates aligned with the amino acid sequence of the prototype PAM gene. 
Isolates were considered PAM-positive if they produced a visible band on X-ray film 
with enhanced chemiluminescent detection (Supersignal
®
 chemiluminescent substrate; 
Pierce, Rockford, IL) following Southern hybridisation, indicating the presence of a 
region with homology to the A1/A2 plasminogen-binding repeat region of PAM. Stars 
indicate residues identical to those of the PAM sequence, while dashes indicate gaps in 
the alignment. Percent amino acid sequence identity to PAM is also given. Despite low 
sequence homology of isolate NS696 with the prototype PAM amino acid sequence, the 
conservation of the lysine residue in the A1 region thought to be critical to plasminogen 
binding capacity of PAM, in addition to positive Southern hybridisation analysis, resulted 
in the PAM-positive designation of this isolate. 
 
Figure 2. 
125
I-plasminogen binding to PAM-positive (●) and PAM-negative (○) group A 
streptococcal isolates from invasive and uncomplicated infections. A. Direct binding of 
125
I-plasminogen. B. Binding of 
125
I-plasminogen in the presence of molar excesses of 
streptokinase and fibrinogen. All estimates were determined in triplicate and data are 
presented as mean. Standard error of the mean was 0-6% of input 
125
I-plasminogen.    
 
Figure 3. Binding of 
125
I-plasminogen to group A streptococcal isolate NS1133 under 
different conditions. 
125
I-plasminogen binding was measured in the presence of the lysine 
analogue, eACA (Plg + eACA); in the presence of no other added reagents (Plg only); in 
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the presence of streptokinase (Plg + Ska); in the presence of fibrinogen (Plg + Fg); and in 
the presence of streptokinase and fibrinogen (Plg + Ska + Fg). All reagents were added in 
molar excess relative to 
125
I-plasminogen. All estimates were determined in triplicate and 
data are presented as mean + SEM. Significant differences, as determined by unpaired t 
test, from the binding of 
125
I-plasminogen alone (Plg only) are marked (*). 
 
Figure 4. Comparison of 
125
I-plasminogen binding to PAM-positive (●) and PAM-
negative (○) group A streptococcal isolates in the presence of streptokinase and 
fibrinogen with ability of the isolates to bind 
125
I-fibrinogen or 
125
I-plasminogen directly. 
All estimates were determined in triplicate and data are presented as mean. Correlation 
curves are shown for relationships with significant correlation.  A. Comparison with 
binding of 
125
I-fibrinogen by group A streptococcal isolates with a correlation curve fitted 
to PAM-positive isolates (r = 0.775, p ≤ 0.002). B. Comparison with direct binding of 
125
I-plasminogen by group A streptococcal isolates with a correlation curve fitted to 
PAM-positive isolates (r = 0.902, p ≤ 0.0001). 
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Table 1. Primers designed for DNA methods  
 
Primer DNA Sequence Use 
SENF1 5’-GGTATGGATGAAAACGACTGGGATG-3’ 
SENR1 5’-TGTCGTGACCAACCTAGTCAGCCTG-3’ 
PCR amplification and 
sequencing of SEN gene 
PAMF1 5'-ATAAGCAAGAACATCTTGACGG-3’ 
PAMR1 5’-CTGTTAATTTCTTGCTTTC-3’ 
PAMF2 5’-AAAGGGCTTAAGACTGATTTAC-3’ 
PAMR2 5’-GACCAGCTAATTTGCTGTTTGC-3’ 
PAMR3 5’-CTTCTCAACATCATCTTTAAGG-3’ 
 
Sequencing of PAM 
genes
a
 
a
PAM gene sequence was determined using M13LacZ forward and universal reverse 
primers (Perkin Elmer, Boston, MA), primers N1 and N2 flanking the plasminogen-
binding site of PAM (5) and the primers listed above, designed to anneal to various sites 
within the PAM gene.  
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Table 2. Characteristics of the 29 NT group A streptococcal isolates  
Isolate  Clinical origin  Invasive 
category
a
 
PAM 
status
b
 
125
I-plg 
binding  
(+SEM;%)  
Enhanced
 
125
I-plg 
binding
c
 
(+SEM;%) 
Vir 
type
d
 
 emm 
sequence  
type
e
 
emm 
pattern
f
 
NS192 renal 
transplant, 
septic (blood) 
inv - 6(+0)% 29(+1)% 3.2 100 E 
NS210 diabetic ulcer 
with fever 
inv - 7(+0)% 29(+2)% 34 22 E 
NS414 wound, 
cellulitis 
inv - 4(+0)% 27(+2)% 3.3 11 E 
NS452 cellulitis/ 
wound 
inv - 7(+0)% 57(+1)% 45 25 E 
NS501 blood inv - 10(+1)% 63(+6)% 61 14 ABC 
NS730 necrotising 
fasciitis, pus 
from left hip 
inv - 11(+0)% 55(+1)% 2.2 90 E 
NS733 necrotising 
fasciitis, wrist 
aspirate 
inv - 5(+1)% 29(+0)% 2.2 90 E 
NS931 necrotising 
fasciitis, blood 
inv - 6(+0)% 52(+3)% 57 69 D 
NS179 pustules on 
foot, 
bacteremia 
inv - 9(+1)% 57(+1)% 7.2 9.1 E 
NS13 blood inv + 81(+2)% 89(+1)% 24 53 D 
NS88.2 blood inv + 54(+1)% 60(+1)% 17.4 98.1 D 
NS223 infected CV 
line (leg), 
blood 
inv + 27(+0)% 55(+2)% 4 91 D 
NS455 blood inv + 30(+1)% 54(+1)% 29.1 52 D 
NS1133 blood inv + 50(+1)% 81(+1)% 17.1 101 D 
NS14 post-operative 
wound 
uncomp - 4(+0)% 27(+0)% 96 102 E 
NS236 sore throat uncomp - 6(+0)% 27(+0)% 111 77 E 
NS244 wound uncomp - 8(+0)% 59(+1)% 14.1 hybrid 
emm4/st
11014 
ABC
g
 
NS297 skin sore uncomp - 6(+1)% 50(+0)% 3.1 44/61 E 
NS474 wound uncomp - 5(+0)% 24(+0)% 22 58 ABC
g
 
NS488 sinusitis/ 
persistent 
pharyngeal pus 
well 
uncomp - 6(+0)% 5(+0)% 52 12 ABC 
NS836 wound uncomp - 5(+0)% 32(+1)% 46 ck249 D 
NS10 throat  uncomp + 44(+2)% 54(+0)% 24 53 D 
NS32 wound uncomp + 34(+0)% 58(+1)% 29.2 101 D 
NS50.1 wound uncomp + 17(+1)% 46(+3)% 12.1 108 D 
NS53 febrile/unwell uncomp + 5(+0)% 35(+1)% 29.1 71 D 
NS59 wound uncomp + 44(+1)% 61(+1)% 24 53 D 
NS253 wound uncomp + 15(+1)% 31(+6)% 29.1 52 D 
NS265 wound uncomp + 5(+0)% 21(+1)% 11 56 D 
NS696 throat swab, 
pharyngitis 
uncomp + 5(+0)% 7(+1)% 78 1 ABC 
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a
 invasive (inv) or uncomplicated (uncomp) GAS infection classification according to 
sterile or nonsterile tissue site of infection, respectively.  
b
 positive (+) or negative (-) plasminogen-binding group A streptococcal M-like protein 
(PAM) status according to hybridisation of M or M-like gene from GAS isolate with an 
oligonucleotide probe homologous to the A1/A2 repeat of the PAM gene by Southern 
analysis. 
c
 Binding of 
125
I-plasminogen to GAS in the presence of excess streptokinase and 
fibrinogen. 
d
 Vir type was determined as previously described (20). 
e
 emm sequence type was determined using a protocol modified from the Streptococcus 
pyogenes emm sequence database (4). 
f
 emm pattern was determined as previously described (6, 24) except that annealing 
temperatures varied between 56°C and 62°C depending on the strain. 
g
 isolates NS244 and NS474 gave an unusual emm pattern, in that PCR product resulted 
only from reaction with primer set 2, rather than sets 1, 2, and 3; or set 1 only as for 
traditional emm pattern ABC. 
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Figure 1 
 
PAM     DAELQRLKNERH---E  EAELERLKSERHD    Percent PAM                                 
Homology         
NS10    ****************  *************       100%              
NS13    ****************  *************       100%              
NS59    ****************  *************       100%              
NS50.1  ****************  ************E       96.5%             
NS1133  A***E**********D  HD******N****        79%              
NS32    A***E**********D  HD******N*G**        76%              
NS53    EVA*E*******VHD*  *V******N****        69%              
NS253   EVA*E*******VHD*  *V******N****        69%              
NS455   EVA*E*******VHD*  *V******N****        69%              
NS223   EV**E*******DHD*  ****N**RE****        69%              
NS265   EVA*E*******VHD*  ********N***Y        65%              
NS88.2  ER**EDL*----***- D***K**NE****        52%              
NS696   WDRQRLE*ELEE**KK  EALAIDQA*RDHY        21%
A1 A2
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Figure 3 
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Figure 4 
